Professor Mark Hatherill

South African Tuberculosis Vaccine Initiative

Professor Mark Hatherill MBChB DCH MRCP FCPaed MMed MD

Director of the South African Tuberculosis Vaccine Initiative (SATVI); Member, Institute of Infectious Disease and Molecular Medicine (IDM); Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town.

SATVI is a world leader in TB vaccine clinical research. Their mission is the development of new and effective vaccination strategies against tuberculosis (TB). They are testing multiple new vaccine candidates in clinical trials; and are involved with projects to address critical clinical, epidemiological, immunological and human genetic questions in TB vaccine development. The initiative's activities are within an academic context, and include the training of postgraduate students and postdoctoral fellows. 

The team of over 100 staff consists of specialists in clinical, epidemiological, human genetic and immunologic science, clinical trials, community liaison, recruitment and follow-up; data management and analysis, disease surveillance, information technology, clinical evaluation and care of participants; facility management, laboratory technology, logistics, research pharmacy management, project management, regulatory affairs, administration, study coordination and training. 

Mark's clinical research interests have focused on design, implementation, and analysis of clinical trials of BCG vaccine and novel TB vaccine candidates; TB diagnostic studies of infection and disease in adult and paediatric study populations; TB therapeutic clinical trials; and the application of TB biomarkers for targeted preventive therapy for people at high-risk of TB.

Selected publications: 

See publications and profile on Research Gate

Contact details:

South African Tuberculosis Vaccine Initiative 
Room S2.01
Wernher and Beit South Building 
Faculty of Health Sciences 
University of Cape Town
Anzio Road 
Observatory, 7925

Tel: +27 21 406 6791
Fax:+27 21 406 6081

Alternate site: 

Group members:

See SATVI Exco

See SATVI investigators:



Mark is the Co-Principal Investigator of the RePORT South Africa network, leader of the AIDS Clincal Trial Group (ACTG) SATVI Site, and collaborates with multiple developers, funders and other stakeholders in the field of novel TB vaccine development: